SNDX-5613 (Revumenib)

Catalog No.S8996 Batch:S899601

Print

Technical Data

Formula

C32H47FN6O4S
Molecular Weight 630.82 CAS No. 2169919-21-3
Solubility (25°C)* In vitro DMSO 25 mg/mL (39.63 mM)
Ethanol 25 mg/mL (39.63 mM)
Water Insoluble
In Vivo (Add solvents to the product individually and in order.)
Homogeneous suspension
CMC-NA
≥5mg/ml Taking the 1 mL working solution as an example, add 5 mg of this product to 1 ml of CMC-Na solution, mix evenly to obtain a homogeneous suspension with a final concentration of 5 mg/ml.
* <1 mg/ml means slightly soluble or insoluble.
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.
* Room temperature shipping (Stability testing shows this product can be shipped without any cooling measures.)

Preparing Stock Solutions

Biological Activity

Description Revumenib(SNDX-5613) is a potent and selective inhibitor of menin-MLL binding with a Ki of 0.15 nM. SNDX-5613 shows anti-proliferative activity against multiple cell lines harbouring MLLr translocations (MV4;11, RS4;11, MOLM-13, KOPN-8) with IC50 values ranging from 10-20 nM.
Targets
menin-MLL binding
0.15 nM(Ki)
In vitro

Revumenib (SNDX-5613) has anti-proliferative activity against multiple cell lines harbouring MLLr translocations (MV4;11, RS4;11, MOLM-13, KOPN-8). It doesn't inhibit growth of HL-60, a promyelocytic leukaemia cell line lacking an MLL rearrangement, indicating selective activity towards leukaemic cell lines that harbour MLL-rearranged (MLLr) fusion proteins.
In Vivo

In aggressive MOLM-13 xenografts nude rats, treatment with Revumenib (SNDX-5613) provides significant survival benefit and leukaemic control.

Protocol (from reference)

Cell Assay:

[1]
  • Cell Lines

    MV4;11, RS4;11, MOLM-13, KOPN-8, HL-60

  • Concentrations

    1-100 nM

  • Incubation Time

    2 h

  • Method

    Using multiple cell lines harboring MLLr translocations (MV4;11, RS4;11, MOLM-13, KOPN-8), the antiproliferative activity of Revumenib (SNDX-5613) against MLLr cell lines was assessed by standard cell proliferation assay.
Animal Study:

[1]
  • Animal Models

    MOLM-13 model rats

  • Dosages

    5, 15, 50 mg/kg

  • Administration

    Oral gavage

References

  • https://www.fda.gov/media/138944/download

Sellecks SNDX-5613 (Revumenib) Has Been Cited by 3 Publications

Enhanced FLI1 accessibility mediates STAG2-mutant leukemogenesis [ bioRxiv, 2025, 2025.04.01.646632] PubMed: 40236115
NAT10-mediated mRNA N4-acetylcytidine reprograms serine metabolism to drive leukaemogenesis and stemness in acute myeloid leukaemia [ Nat Cell Biol, 2024, ] PubMed: 39506072
Synergistic Effects of the RARalpha Agonist Tamibarotene and the Menin Inhibitor Revumenib in Acute Myeloid Leukemia Cells with KMT2A Rearrangement or NPM1 Mutation [ Cancers (Basel), 2024, 16(7)1311] PubMed: 38610989

RETURN POLICY
Selleck Chemical’s Unconditional Return Policy ensures a smooth online shopping experience for our customers. If you are in any way unsatisfied with your purchase, you may return any item(s) within 7 days of receiving it. In the event of product quality issues, either protocol related or product related problems, you may return any item(s) within 365 days from the original purchase date. Please follow the instructions below when returning products.

SHIPPING AND STORAGE
Selleck products are transported at room temperature. If you receive the product at room temperature, please rest assured, the Selleck Quality Inspection Department has conducted experiments to verify that the normal temperature placement of one month will not affect the biological activity of powder products. After collecting, please store the product according to the requirements described in the datasheet. Most Selleck products are stable under the recommended conditions.

NOT FOR HUMAN, VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.